The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial

Lancet

Volumn 353, Issue 9146, 1999, Pages 9-13

  Dargie, H J ^b   Lechat, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0033514046     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11181-9     Document Type: Article

References (21)

1. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
2. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-year follow-up of patients randomised in the Metoprolol in Dilated Cardiomyopathy Trial. Lancet 1998; 351: 1180-81.
3. Australia and New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
4. Doughty R.N., Rodgers A., Sharpe N., MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trials. Eur Heart J. 8:1997;560-565.
5. Heidenrich P.A., Lee T.T., Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 30:1997;27-34.
6. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., Boissel J.P. Beta-blockers in heart failure: meta-analysis of randomized trials. Circulation. 98:1998;1184-1191.
7. Haeusler G, Schliep HJ, Schelling P, et al. High ß1 selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol 1986; 8 (suppl II): S2-15.
8. CIBIS investigators and committees. A randomized trial of ß-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
9. The CIBIS-II Scientific Committee. Design of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II). Fund Clin Pharmacol 1997; 11: 38-42.
10. Peto R., Pike M.C., Armitage Pet al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient, I: introduction and design. Br J Cancer. 34:1976;585-612.
11. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-56.
12. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high risk and low risk patients after myocardial infarction. N Engl J Med. 339:1998;489-497.
13. Packer M, Bristow MR, Cohn J, et al for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
14. Pousset F., Copie X., Lechat Pet al. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol. 77:1996;612-617.
15. Copie X, Pousset F, Lechat P, Jaillon P, Guize L, Le Heuzey JY, and the Cardiac Insufficiency Bisoprolol Study Investigators. Effects of beta-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of RR intervals at selected heart rates. Am Heart J 1996; 132: 369-75.
16. Leiger RE, Miller JP, Bigger JT, Moss AJ and the multicenter post-infarction research group. Decreased heart rate variability and its association with increased mortality after myocardial infarction. Am J Cardiol 1987; 59: 256-62.
17. Nolan J., Batin P., Andrews Ret al. Prospective study of heart rate variability and mortality in chronic heart failure:results of the United Kingdom Heart Failure Evaluation and Assessment Trial (UK-Heart). Circulation. 98:1998;1510-1516.
18. Bristow M, Gilbert EM, Abraham WT, et al for the MOCHA investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 4: 2807-16.
19. Lechat P, Escolano S, Golmard JL, et al on behalf of CIBIS investigators. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study. Circulation 1997; 96: 2197-205.
20. The BEST Steering Committee. Design of the Beta-blocker Evaluation Survival Trial. Am J Cardiol 1995;75: 1220-23.
21. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371.